Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Expenses (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Accumulated Expenses for 11 consecutive years, with $111.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 35.66% to $111.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $111.2 million, a 35.66% increase, with the full-year FY2025 number at $111.2 million, up 35.66% from a year prior.
  • Accumulated Expenses was $111.2 million for Q4 2025 at Iovance Biotherapeutics, up from $87.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $111.2 million in Q4 2025 to a low of $13.9 million in Q1 2023.
  • A 3-year average of $66.7 million and a median of $75.7 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: grew 18.05% in 2024, then surged 296.5% in 2025.
  • Iovance Biotherapeutics' Accumulated Expenses stood at $69.4 million in 2023, then increased by 18.05% to $81.9 million in 2024, then surged by 35.66% to $111.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Accumulated Expenses are $111.2 million (Q4 2025), $87.3 million (Q3 2025), and $89.1 million (Q2 2025).